Drug Interaction Report

ADJUST DOSING INTERVAL: Concurrent use of the autologous genome edited hematopoietic stem cell-based gene therapy exagamglogene autotemcel with myeloablative conditioning agents, such as busulfan, may lead to destruction of the newly edited stem cells. However, clinical data on the use of exagamglogene autotemcel before elimination of the myeloablative conditioning regimen are not available.

MANAGEMENT: The manufacturer recommends administering exagamglogene autotemcel between a minimum of 48 hours and a maximum of 7 days after the last dose of the myeloablative conditioning regimen, to allow for the elimination of the myeloablative conditioning agent from the body.